Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Sierra Sciences' Plan to Cure Aging is Validated by Newly Published Proof of Concept Experiment


News provided by

Sierra Sciences, LLC

Nov 30, 2010, 05:32 ET

Share this article

Share toX

Share this article

Share toX

RENO, Nev., Nov. 30, 2010 /PRNewswire/ -- On Sunday, a team of scientists at Harvard Medical School led by Dr. Ronald DePinho published research providing strong scientific support for the validity of Sierra Sciences' approach to curing aging.  Their research demonstrated for the first time that turning on telomerase and lengthening telomeres will reverse the symptoms of old age in a living animal.  These findings appear as a research article entitled 'Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice', published November 28, 2010 ahead of print in the peer-reviewed journal Nature.  The article can be found at http://www.nature.com/nature/journal/vaop/ncurrent/pdf/nature09603.pdf.

For decades, many scientists have believed that the theoretical 125-year limit on human lifespan, and the decline in our health in old age, is imposed by the gradual shortening of our telomeres.  Telomeres are structures at the ends of our chromosomes that shorten with every cell division, and telomere shortening has been theorized to be the "clock of aging" contained within the human body.  Evidence has been mounting that this hypothesis is correct, and in 2009, the Nobel Prize in Medicine was awarded to scientists who originally characterized telomeres and telomerase.  However, Dr. DePinho's research is possibly the strongest proof of concept for this hypothesis yet.

This research was built upon earlier studies and experiments on mice.  In the wild, mice do not age the same way as humans; they produce telomerase throughout their lives and generally die because they are lacking several important defenses against oxidative stress that humans possess.  However, since 1999, it has been possible to disable the telomerase gene in mice.  After breeding telomerase-deficient mice for six to seven generations, scientists have been able to create strains of "telomerase knockout" mice that do age like humans, and show classical symptoms of human aging including graying hair, frailness, spontaneous malignancies, etc.

In Dr. DePinho's experiment, instead of disabling the telomerase gene, his team constructed a version of telomerase that is completely inactive until it is introduced to the drug 4-hydroxytamoxifen.  They created a line of mice with this altered form of telomerase, and then bred them for several generations, until the telomeres of these mice became short enough that they began to display human-like symptoms of aging.  Then, they introduced 4-hydroxytamoxifen to the mice, activating the telomerase in their cells.

The team found that this treatment successfully decreased the abundance of cells with critically short telomeres in these mice.  More significantly, this allowed resumption of cell proliferation, and eliminated the symptoms of degeneration across multiple organs, including the testes, spleens, and intestines.  It also reversed neurodegeneration in the mice, causing proliferation of new neurons and increasing the animals' brain weight.  These were results that, if seen in elderly humans, would constitute a successful reversal of the aging process.

Human cells are capable of producing telomerase, but do not do so under most circumstances.  We possess a genetic "switch" that controls expression of telomerase, but, unlike the mice that were altered to respond to 4-hydroxytamoxifen, we don't know exactly what chemical turns telomerase on in our bodies.  However, over the past eleven years, Sierra Sciences' research under the leadership of Dr. Bill Andrews has led to the discovery of 38 distinct drugs that cause some de-repression of the telomerase gene.  Further medicinal chemistry should enable the discovery of the exact chemical that turns on telomerase in humans.

Sierra Sciences has also developed mechanisms for screening thousands of natural products a week for telomerase induction, and expects to be able to launch a nutraceutical that turns on telomerase in humans by early 2011.  Dr. Andrews and Sierra Sciences have entered into a partnership with John Anderson, founder of Isagenix, International and CEO of Dream Master Laboratories, a manufacturer and formulator of natural products, to quickly bring this nutraceutical to market.

"Telomere shortening has a role in a vast number of diseases," said Dr. Andrews.  "We see telomere shortening as a primary culprit in everything from atherosclerosis to osteoporosis to macular degeneration; really, any disease you're more likely to suffer from at age 70 than age 30 probably has something to do with telomere shortening.  Just as telomerase activation reversed degeneration in the organs of these mice, we expect that it can do the same for humans.  Telomerase activation technology promises to be the most significant advance in human health since germ theory."

Significantly, the mice in Dr. DePinho's experiment did not suffer from an increased risk of cancer over the four-week course of their treatment with 4-hydroxytamoxifen, and inducing telomerase increased the median survival of these mice over that four-week period.  It has been hypothesized that telomerase activation in humans could lead to cancer, but that hypothesis has never been experimentally validated.

"This study is really just another nail in the coffin for the idea that telomerase induction would lead to cancer," said Dr. Andrews.  "Even as early as 2002, a review of 86 publications showed that telomerase is not a carcinogen or oncogene.  And research within the past two years has shown that short telomeres are actually a very significant risk factor for both the incidence and the mortality of cancer, and that lengthening telomeres by inducing telomerase should actually prevent cancer.

"It might have once seemed intuitive to suggest that, because 85% to 95% of cancer cells express telomerase, telomerase was a cause of cancer," Dr. Andrews said.  "But, now, the evidence is in, and it's become absolutely clear: telomerase does not cause cancer.  Cancer causes telomerase, but telomerase does not cause cancer."

ABOUT SIERRA SCIENCES

Sierra Sciences LLC (www.sierrasci.com) is a company devoted to finding ways to extend our health span and lifespan beyond the theoretical maximum of 125 years.  Sierra Sciences was founded by Dr. William H. Andrews to continue his anti-aging research and to commercially exploit the results by developing a pharmaceutical to prevent and/or reverse cellular aging. We are pursuing basic research to develop a pharmaceutical that will cause the endogenous telomerase gene to express an enzyme called telomerase which has been shown to extend telomeres, thus restoring cells to youthful vigor.

SOURCE Sierra Sciences, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.